Compare Charles River Laboratories Intl. Inc (CRL) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Raytheon Technologies Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $226.38 (market cap $11.14B), while Raytheon Technologies Corp trades at $194.56 (market cap $260.44B). The key difference: Raytheon Technologies Corp is far larger — about 23.4× Charles River Laboratories Intl. Inc's market cap, and Raytheon Technologies Corp pays a 1.51% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | RTX | |
|---|---|---|
Market Cap | $11.14B | $260.44B |
Sector | Health | Industrials |
52-Week High | $233.60 | $212.16 |
52-Week Low | $145.57 | $148.68 |
Enterprise Value | $14.00B | $292.55B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
RTX trades at $196.39, up 0.23% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $1.78 surpassing the $1.51 expectation. Revenue grew to $88.6B in 2025, and net income margin improved to 8.03%. The company secured a $515 million Navy contract for SPY-6 radars, highlighting defense sector strength. Cash flow from operations reached $10.57B in 2025, supporting dividend payments and strategic investments.
The outlook for RTX is positive, driven by robust defense contracts, earnings growth, and a consensus price target of $213. Risks include reliance on government spending, competitive pressures, and macroeconomic volatility. Institutional sentiment remains bullish with 69% buy ratings, but investors should monitor debt levels and execution on production targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
